Roles
- Associate Professor of Clinical Medicine
-
Biography
Dr. Hoffman is a hematologist/oncologist that received his bachelor’s degree from Columbia University and his medical degree from Albert Einstein College of Medicine. He completed his internal medicine residency and chief residency at NYU Medical Center, and his fellowship at Memorial Sloan-Kettering Cancer Center. He specializes in the treatment of all plasma cell disorders- with a specific research and clinical focus on Amyloidosis. He has authored numerous articles in the peer-reviewed literature. He is the Associate Director of the Hematology/Oncology fellowship program and teaches the first year hematology course at the University of Miami Miller School of Medicine, where he also oversees the entire oncology curriculum over the 4 year program. -
Education & Training
Education
Post Graduate Training
Licensures and Certifications
-
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Articles & News
2026 Faculty Awards Celebrate Excellence Across the Miller School of Medicine and UHealth
Dean’s Faculty Awards: Celebrating Academic and Clinical Excellence
Disclaimer:
Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 8 clinical trials.
-
To test an investigation product(s) called ABBV-383 in patients with Amyloidosis in order to be able to answer specific questions such as: Does this study product work?, Is it safe?, What kind of treatment is better?
- Principal Investigator: James Hoffman
- Study Phase: Phase I
- Enrollment Status: Open
-
To see if an investigational drug, acoramidis (AG10), is safe and effective in preventing or delaying symptoms of a disease called Transthyretin Amyloidosis (ATTR).
- Principal Investigator: James Hoffman
- Study Phase: Phase III
- Enrollment Status: Open
-
To compare major organ deterioration progression-free survival between participants randomized to the ASCT and non-ASCT arms of this study.
- Principal Investigator: James Hoffman
- Study Phase: Phase III
- Enrollment Status: Open
-
Phase 1/2 FIH Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Patients With Relapsed or Refractory Multiple Myeloma
- Principal Investigator: James Hoffman
- Study Phase: Phase 1/Phase 2
- Enrollment Status: Not Accepting
-
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects With Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTRibute-CM Trial)
- Principal Investigator: James Hoffman
- Study Phase: Phase 3
- Enrollment Status: Closed
-
A Phase 1 Study of SEA-BCMA in Patients With Relapsed or Refractory Multiple Myeloma
- Principal Investigator: James Hoffman
- Study Phase: Phase 1
- Enrollment Status: Closed
-
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
- Principal Investigator: James Hoffman
- Study Phase: Phase 3
- Enrollment Status: Not Accepting
-
A PHASE 3 MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826-83) 20 MG OR 80 MG [OR TAFAMIDIS (PF-06291826-00) 61 MG] IN SUBJECTS DIAGNOSED WITH TRANSTHYRETIN CARDIOMYOPATHY (ATTR-CM)
- Principal Investigator: James Hoffman
- Study Phase: Phase 3
- Enrollment Status: Closed
